Expression of the transcriptional coregulator FHL2 in human breast cancer: A clinicopathologic study

OBJECTIVE: Although the Four and a Half LIM domain protein 2 (FHL2) has been suggested to play an important role in tumor development, this has not been investigated in breast cancer. METHODS: Paraffin-embedded tissues from patients (n = 85) with primary breast cancer were submitted to immunohistochemical investigation of FHL2 expression and subsequent correlation with clinicopatholic parameters and patient survival. RESULTS: The expresssion of FHL2 was confined to the cytoplasm of the tumor cells. Fortty (47%) of 85 samples showed weak expression of FHL2, whereas high expression was found in 45 tumors (53%). A statistically significant positive correlation was observed between FHL2 and androgen receptor expression (P = .029). Patients with tumors expressing low amounts of FHL2 were characterized by a signficantly better survival compared to those with high intratumoral FHL2 expression (P = .0215, log-rank test). The additional stratification according to adjuvant tamoxifen treatment revealed a significantly improved survival rate for patients receiving tamoxifen and being diagnosed with a tumor expressing high amounts of FHL2. This might indicate that tamoxifen is at least partially capable of reversing the negative prognostic impact of high FHL2 expression. Multivariate Cox regression analysis revealed FHL2 expression as a significant independent predictor of survival. CONCLUSION: The specific expression in tumor tissue points to an important functional role of FHL2 in human, breast cancer. Our survival data indicate that the expression of FHL2 in primary breast cancer factor. Further studies are warranted to elucidate whether analysis is a potentially relevant prqqnostic FHL2 expression is suitable to predict response to antihormonal treatment with tamoxifen.